Collaboration Data Sample Clauses

Collaboration Data. Each Party shall use good scientific practices and shall comply in all material respects with applicable regulations and customary good laboratory and clinical practices in the performance of the Research Program (including all data in the form required to be maintained under any applicable governmental regulations). Such records shall comprise books, results, reports, research notes, charts, graphs, comments, computations, analyses, recordings, photographs, computer programs and documentation thereof, computer information storage means, samples of materials and other graphic or written data generated in connection with the Research Program. Each Party shall provide the other Party the right to inspect its data, and shall provide summaries of its data, to the extent reasonably required for the performance of each Party's obligations under this Agreement and the Research Plan; provided, however, that each Party shall maintain such records and the information of the other Party contained therein in confidence in accordance with Article XI below and shall not use such records or information of the other Party except to the extent otherwise permitted by this Agreement.
Sample 1
AutoNDA by SimpleDocs
Collaboration Data. Each Party shall use good scientific practices and shall comply in all material respects with applicable regulations and customary good laboratory and clinical practices in the performance of the evaluation activities hereunder and under any Statement of Work (including all data in the form required to be maintained under any applicable governmental regulations). Such records shall comprise books, results, reports, research notes, charts, graphs, comments, computations, analyses, recordings, photographs, computer programs and documentation thereof, computer information storage means, samples of materials and other graphic or written data generated in connection with such evaluation activities. Any such data developed by employees of SBI, or others on behalf of SBI, shall be owned by SBI (“SBI Data”) and any such data developed by employees of ABI, or others on behalf of ABI, shall be owned by ABI (“ABI Data”). For purposes of evaluation of mutual performance of the objectives defined in the Statement of Work and to support regulatory filings, each Party shall provide summaries of its Data, to the extent reasonably required. Each Party shall maintain such data in confidence in accordance with Section 4.3 above and Appendix C hereto and shall not use such data of the other Party except to the extent otherwise permitted by this Agreement or consented by the other Party.
Sample 1
Collaboration Data. Cortex shall use good scientific ------------------ practices, and Shire shall use reasonable efforts to comply in all material respects with applicable regulations and customary good clinical practices in the performance of the Research Plan and Development Plan hereunder (including all data in the form required to be maintained under any applicable governmental regulations). Such records shall comprise books, results, reports, research notes, charts, graphs, comments, computations, analyses, recordings, photographs, computer programs and documentation thereof, computer information storage means, samples of materials and other graphic or written data generated in connection with the Research Plan and Development Plan. Any such data developed by employees of Cortex, or others on behalf of Cortex, shall be owned by Cortex ("Cortex Data") and any such data developed by employees of Shire, or others on behalf of Shire, shall be owned by Shire ("Shire Data"). Each Party shall provide the other Party the right to inspect its Data, and shall provide summaries of its Data, to the extent reasonably required for the performance of each Party's obligations under this Agreement; provided, however, that each Party shall maintain such records and the information of the other Party contained therein in confidence in accordance with Article 10 below and shall not use such records or information of the other Party except to the extent otherwise permitted by this Agreement.
Sample 1
Collaboration Data. Each Party shall use good scientific practices and shall comply in all material respects with applicable regulations and customary good laboratory and clinical practices in the performance of the Joint Development Program (including all data in the form required to be maintained under any applicable governmental regulations). Such records shall comprise books, results, reports, research notes, charts, graphs, comments, computations, analyses, recordings, photographs, computer programs and documentation thereof, computer information storage means, samples of materials and other graphic or written data generated in connection with the Joint Development Program. Each Party shall provide the other Party the right to inspect its data upon reasonable notice and not more than once per year, and shall provide summaries of its data, to the extent reasonably required for the performance of each Party's obligations under this Agreement and the Joint Development Program; provided, however, such records will be considered to be Confidential Information of the disclosing Party and each Party will maintain such Confidential Information in confidence in accordance with Section 8 and shall not use
Sample 1
Collaboration Data. All data (including any raw data, clinical data, non-clinical data, and any related information, analyses, and reports as available), other than the FibroGen Other Collaboration Data, generated by or on behalf of either Party during the performance of Development Activities and Evaluation Activities under the Study Plan (“Collaboration Data”) will be solely owned by Xxxxxx and will be deemed to be Collaboration Know-How.
Sample 1
Collaboration Data. To the extent that Revance or its Affiliates or their Sublicensees utilize the Collaboration Data, or any Regulatory Filings, Marketing Authorizations, regulatory communications or Product-Related Data provided by Mylan pursuant to Section 5.5, to Exploit the Product in [*], Revance shall pay Mylan a [*] royalty on Net Sales of the Product in Japan until Revance has paid to Mylan [*] in the aggregate in royalties under this Section 2.2(c). Except as expressly set forth in this Agreement, Revance and its Affiliates shall not use, or grant any Third Party rights to use, any Collaboration Data for purposes of, directly or indirectly, developing, manufacturing or commercializing the Product or any Competing Product.
Sample 1
Collaboration Data. Collaboration Data shall be shared and disclosed between the Parties on a regular basis through the Term of the Collaboration. Collaboration Data that relate specifically and exclusively to RTI Technology shall be considered the Confidential Information of RTI owned by RTI, notwithstanding which Party first disclosed such data to the other Party. Collaboration Data that relate to Athersys Technology, including data regarding cell media, cell potency, cell differentiation and cell performance characteristics, shall be considered the Confidential Information of Athersys owned by Athersys, notwithstanding which Party first disclosed such data to the other Party. Collaboration Data that would be used ordinarily for regulatory, business development, or commercialization purposes, including the MAPC Technology Product’s identity, application and performance, or any other Collaboration Data that are not specified as the Confidential Information of RTI or Confidential Information of Athersys shall be considered the Confidential Information of both Parties and owned jointly by both Parties (“Jointly Owned Collaboration Data”), notwithstanding which Party first disclosed such data or information to the other Party.
Sample 1
AutoNDA by SimpleDocs
Collaboration Data. Notwithstanding anything to the contrary herein, Buyer shall own all Collaboration Data. Neither Parent nor Synlogic shall have any rights, title or interest in or to any such Collaboration Data except for a limited right to use Collaboration Data for the following purposes if and to the extent approved by the JRC:
Sample 1

Related to Collaboration Data

  • Collaboration Each Party shall provide to the enforcing Party reasonable assistance in such enforcement, at such enforcing Party’s request and expense, including to be named in such action if required by Applicable Laws to pursue such action. The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, shall reasonably consider the other Party’s comments on any such efforts, including determination of litigation strategy and filing of material papers to the competent court. The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the enforcing Party.

  • Research Collaboration (a) GSK hereby grants to Anacor a non-exclusive, non-royalty bearing license under the GSK IP, solely as and to the extent necessary or important to conduct activities for which Anacor is responsible under the Research Plans during the Research Collaboration Term.

  • Clinical Data The descriptions of the results of any studies and tests conducted by or on behalf of, or sponsored by, the Company or its subsidiaries, or in which the Company has participated, that are described in the Disclosure Package and the Prospectus, or the results of which are referred to in the Disclosure Package and the Prospectus do not contain any misstatement of material fact or omit to state a material fact necessary to make such statements not misleading. The Company has no knowledge of any studies or tests not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Disclosure Package or Prospectus.

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Research Program Term The Research Program shall be conducted during the period of five years commencing as of the Agreement Date ("Research Program Term"). Upon not later than seventy-five (75) days' prior written notice JT may, in its sole judgment, terminate the Research Program at the end of the third (3/rd/) year and fourth (4/th/) year of the Research Program. The RMC may terminate the Research Program any time during the Research Program Term if it unanimously determines the Research Program is no longer scientifically useful or that all potential Products would not be commercially viable. In case of such an early termination by JT or the RMC, JT shall be exempt from any payment(s) under Section 10(a) that would have become due and payable after the effective date of such early termination. Following any termination of the Research Program (i) that occurs simultaneously with the termination of this Agreement in accordance with Section 13 (i.e., no compound or Lead Compound has been designated previously a Collaboration Lead Compound in accordance with Section 3(b) and no Independent Lead Compound is being developed in accordance with Section 3(m)) or (ii) that is followed at some future date by the termination by JT of Development or co-promotion of any Collaboration Lead Compound and/or Product pursuant to Sections 3(l) or 5(c), respectively, or development of an Independent Lead Compound in accordance with Section 3(m) (A) any licenses granted by Tularik to JT will terminate, (B) JT will grant to Tularik an exclusive, sublicensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under JT's interest in Program Patents and Program Know-How and (C) under the terms and conditions to be separately agreed, JT will also grant to Tularik a nonexclusive, sublicensable, worldwide license under any JT Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How in (B) (including, with respect to compounds, a limited number of JT's library compounds approved by JT); provided, however, that in the event the Research Program terminates but the Agreement has not terminated with respect to designated Collaboration Lead Compounds, Independent Lead Compounds and/or Products as provided in Section 2(g)(ii), Sections 2(g)(A), (B) and (C) shall apply only to those compounds, Collaboration Lead Compounds, Independent Lead Compounds and Products for which Development or co-promotion shall have been terminated and/or to those compounds or Lead Compounds that have not been designated previously a Collaboration Lead Compound in accordance with Section 3(b) or an Independent Lead Compound in accordance with Section 3(m); provided further that in the event that JT elects to pursue a Discontinued Compound or a Non-Proposed Compound on or before the first anniversary of the expiration or termination of the Research Program Term pursuant to Section 3(b)(iii) or 3(b)(iv), respectively, Sections 2(g)(A), (B) and (C) shall not apply to such Discontinued Compound or Non-Proposed Compound until such time as JT shall have terminated the Development or co-promotion of such Discontinued Compound or Non- Proposed Compound. Tularik will then be free to pursue clinical development and registration of such compounds, Lead Compounds and/or Products without obligation to JT except as provided in Section 4(f) or Section 5(c), as appropriate.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Development Program A. Development Activities to be Undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Third Party Technology The assignment of any applicable license agreements with respect to Third Party Technology are set forth in the General Assignment and Assumption Agreement.

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

Time is Money Join Law Insider Premium to draft better contracts faster.